A Double-Blind, Randomized-Withdawal, Placebo-Controlled

Project: Research project

Description

A Double-Blind, Randomized-Withdawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-Esterase Inhibitor as add-on Standard of care for the treatment of Refractory antibody
StatusActive
Effective start/end date5/1/175/30/23

Funding

  • CSL BEHRING GMBH

Fingerprint

Complement C1 Inhibitor Protein
Standard of Care
Placebos
Safety
Antibodies
Therapeutics